Clinical trials: Hemostatic Disorders
Plasma Cell Myeloma
Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma
This trial studies how well exercise prescription works in improving quality of life in elderly patients with multiple myeloma. Engaging and adhering to an exercise program may improve functional status and quality of life and…
- Trial name
- NCT04100044
- Testing
- Exercise Counseling, Exercise Intervention, Questionnaire administration
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Thomas Jefferson University
Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation
BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
Trial for patients with refractory multiple myeloma after failure of at least two treatment regimens and with BRAFV600E/K Mutation to evaluate the efficacy of the kinase inhibitors Encorafenib (LGX818 in) combination with…
- Trial name
- GMMG-BIRMA (NCT02834364)
- Testing
- Encorafenib, Binimetinib
- Where
- 7 sites in Germany
- Volunteers
- 12 people
- Sponsor
- University of Heidelberg Medical Center
Multiple Myeloma, Plasma Cell Neoplasm
Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma
RATIONALE: Chemoprotective agents may protect normal cells from the side effects of chemotherapy. Ice chips or saline mouth rinse may lessen the severity or help prevent symptoms of mucositis or mouth sores in patients receiving…
- Trial name
- NCT00118339
- Testing
- chemoprotection, complementary or alternative medicine procedure, management of therapy complications
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Fred Hutchinson Cancer Center
Waldenstrom Macroglobulinemia, Treatment Naive
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
In Waldenström's macroglobulinemia (WM) chemotherapy induces only low CR/VGPR rates and response duration is limited. In addition, WM patients are often elderly, partly not tolerating chemotherapy related toxicities.
- Trial name
- VIWA-1 (NCT05099471)
- Testing
- Venetoclax; Rituximab, DRC
- Where
- 14 sites in Germany, Greece
- Volunteers
- 80 people
- Sponsor
- Christian Buske
Waldenström Macroglobulinemia
The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
The purpose of this study is to evaluate the efficiency of an oral regimen in newly diagnosed Waldenström macroglobulinemia: thalidomide plus cyclophosphamide and dexamethasone following by thalidomide and prednisone maintenance…
- Trial name
- BDH-WM02 (NCT02844309)
- Testing
- Thalidomide
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Recurrent Plasma Cell Myeloma
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant.
- Trial name
- NCT03622775
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Trial name
- NCT04162119
- Testing
- BCMA-PD1-CART Cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Premature Infant, Hemostasis
Normal Hemostasis Values in Premature Infants
This study aims to retrospectively determine, in a large cohort of apparently healthy children born before 37 weeks of gestation, the expected values of certain hemostasis parameters from birth to 18 months (when they start…
- Trial name
- PRHEMO (NCT07349251)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Strasbourg, France
Cancer, Neoplasms
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
This is an open-label, multicenter, 2-part study to determine the recommended Phase 2 dose (RP2D) for GSK2816126 given twice weekly by intravenous (IV) infusion.
- Trial name
- NCT02082977
- Testing
- GSK2816126
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Plasma Cell Myeloma
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma.
- Trial name
- NCT05208307
- Testing
- Belantamab Mafodotin, Dexamethasone, Pomalidomide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Emory University
Multiple Myeloma, Non-Hodgkin's Lymphoma
A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
The trial is an open label Simon optimal two-stage Phase II trial of fixed doses of oral meloxicam and subcutaneous filgrastim to assess the safety and efficacy in mobilizing autologous peripheral blood stem cells (PBSC) from…
- Trial name
- NCT02078102
- Testing
- Meloxicam, Filgrastim
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sherif S. Farag
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well panobinostat, carfilzomib, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT03256045
- Testing
- Carfilzomib, Chemosensitivity Assay, Dexamethasone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Washington
Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient
Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System
The thrombin generation test is a global test for the study of coagulation that allows the fine study of the balance between procoagulant and anticoagulant factors.
- Conditions
- Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient, Patient With FV Leiden Mutation, Patient With Cirrhosis
- Trial name
- EVIGE (NCT05422157)
- Where
- France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hematologic Cancer
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of…
- Trial name
- NCT05753501
- Testing
- ABBV-101, Venetoclax
- Where
- 51 sites in United States, Canada and 7 more
- Volunteers
- 135 people
- Sponsor
- AbbVie
Blood Loss, Surgical
HemoSonics - UTMB Cardiac Surgery Study
This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the Quantra QPlus Cartridge in patients undergoing cardiac surgery utilizing cardiopulmonary bypass, including the…
- Trial name
- NCT03988465
- Testing
- Quantra System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- HemoSonics LLC
Hemophilia A, Hemophilia A, Severe
Hemophilia A Research Program
This study longitudinally observes the intergenerational (mother-child) continuum in hemophilia A from pregnancy through early childhood.
- Conditions
- Hemophilia A, Hemophilia A, Severe, Factor VIII (FVIII), FVIII Deficiency
- Trial name
- HARP (NCT07414511)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Washington
Multiple Myeloma
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
H9S-MC-JDCF was a multicenter non-randomized, single-arm, open-label, dose-escalation, dose confirmation, Phase 1 study of intravenous (IV) LY2127399 in combination with bortezomib in patients with refractory or relapsed MM.
- Trial name
- NCT00689507
- Testing
- LY2127399
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Applied Molecular Evolution
Blood Coagulation Disorders
Dental Extractions in Patients Under Dual Antiplatelet Therapy
The purpose of this study is to compare two hemostatic agents in patients under dual antiplatelet therapy using the intraoral bleeding time after dental extractions.
- Trial name
- DUALex (NCT02918045)
- Testing
- HemCon Dental Dressing, Oxidized Cellulose Gauze
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Multiple Myeloma and Plasma Cell Neoplasm
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004072
- Testing
- O6-benzylguanine, carmustine
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma
RMPT for Relapsed/Refractory Multiple Myeloma
After the discovery of melphalan and prednisone (MP), many clinical trials evaluated the efficacy of combination chemotherapy, such as VMCP, VBAP, MOCCA in multiple myeloma (MM) patients, without significant clinical benefit.
- Trial name
- RMPT (NCT00961467)
- Testing
- Revlimid, Melphalan, Prednisone, Thalidomide
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Fondazione EMN Italy Onlus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.